HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy

Background and objectives HIV among people who inject drugs (PWID) is a major public health concern in Eastern and Central Europe and Central Asia. HIV transmission in this group is growing and over 27 000 HIV cases were diagnosed among PWID in 2010 alone. The objective of this systematic review was to examine risk factors associated with HIV prevalence among PWID in Central and Eastern Europe and Central Asia and to describe the response to HIV in this population and the policy environments in which they live. Design A systematic review of peer-reviewed and grey literature addressing HIV prevalence and risk factors for HIV prevalence among PWID and a synthesis of key resources describing the response to HIV in this population. We used a comprehensive search strategy across multiple electronic databases to collect original research papers addressing HIV prevalence and risk factors among PWID since 2005. We summarised the extent of key harm reduction interventions, and using a simple index of ‘enabling’ environment described the policy environments in which they are implemented. Studies reviewed Of the 5644 research papers identified from electronic databases and 40 documents collected from our grey literature search, 70 documents provided unique estimates of HIV and 14 provided multivariate risk factors for HIV among PWID. Results HIV prevalence varies widely, with generally low or medium (<5%) prevalence in Central Europe and high (>10%) prevalence in Eastern Europe. We found evidence for a number of structural factors associated with HIV including gender, socio-economic position and contact with law enforcement agencies. Conclusions The HIV epidemic among PWID in the region is varied, with the greatest burden generally in Eastern Europe. Data suggest that the current response to HIV among PWID is insufficient, and hindered by multiple environmental barriers including restricted access to services and unsupportive policy or social environments.

[1]  K. Blankenship,et al.  Addressing the 'Risk Environment' for Injection Drug Users: The Mysterious Case of the Missing Cop , 2004, The Milbank quarterly.

[2]  Kate Shannon,et al.  Structural Violence and Structural Vulnerability Within the Risk Environment: Theoretical and Methodological Perspectives for a Social Epidemiology of HIV Risk Among Injection Drug Users and Sex Workers , 2011 .

[3]  L. Johnston,et al.  Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro , 2009, BMC infectious diseases.

[4]  Kate Swaffer,et al.  'Nothing about us without us!'. , 1993, New Zealand health & hospital.

[5]  K. Nelson,et al.  Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A Population-Based Survey of the Adult Population of T'bilisi, Republic of Georgia , 2006, Journal of Urban Health.

[6]  M. Davoli,et al.  Drug-related mortality and its impact on adult mortality in eight European countries. , 2006, European journal of public health.

[7]  T. Rhodes,et al.  Harm Reduction: Evidence, Impacts and Challenges , 2010 .

[8]  T. Rhodes,et al.  Impact of Gender and Sex Work on Sexual and Injecting Risk Behaviors and Their Association With HIV Positivity Among Injecting Drug Users in an HIV Epidemic in Togliatti City, Russian Federation , 2005, Sexually transmitted diseases.

[9]  T. Rhodes,et al.  Policing Drug Users in Russia: Risk, Fear, and Structural Violence , 2010, Substance use & misuse.

[10]  W. Miller,et al.  HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia , 2006, AIDS.

[11]  J. Carr,et al.  High HIV prevalence and risk factors among injection drug users in Tashkent, Uzbekistan, 2003-2004. , 2006, Drug and alcohol dependence.

[12]  C. Latkin,et al.  Unprotected Sex in Heterosexual Partnerships of Injecting Drug Users in St. Petersburg, Russia , 2010, AIDS and Behavior.

[13]  Crime.,et al.  WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users.. , 2009 .

[14]  Captain Y. B. Nusfield.  Public Health , 1906, Canadian Medical Association journal.

[15]  U. Unicef,et al.  Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. , 2011 .

[16]  J B Brunet,et al.  [AIDS surveillance in Europe]. , 1986, Revue d'epidemiologie et de sante publique.

[17]  D Burrows,et al.  HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. , 1999, Addiction.

[18]  R. Coutinho,et al.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.

[19]  P. Stolley,et al.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.

[20]  E. Sumartojo.  Structural factors in HIV prevention: concepts, examples, and implications for research , 2000, AIDS.

[21]  T. Rhodes.  Risk environments and drug harms: a social science for harm reduction approach. , 2009, The International journal on drug policy.

[22]  J. Carr,et al.  Short report: HIV infection among commercial sex workers and injecting drug users in the Czech Republic. , 2006, The American journal of tropical medicine and hygiene.

[23]  Adrian Renton,et al.  Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. , 2003, Social science & medicine.

[24]  Matt Anderson,et al.  European Monitoring Centre for Drugs and Drug Addiction , 2014 .

[25]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[26]  J. Shearer.  Interventions for Amphetamine Misuse , 2010 .

[27]  T. Krasnoselskikh,et al.  Sexually Transmitted Infections, Sexual Risk Behaviors and the Risk of Heterosexual Spread of HIV among and beyond IDUs in St. Petersburg, Russia , 2008, European Addiction Research.

[28]  D. D. Jarlais,et al.  HIV risk behaviour among participants of syringe exchange programmes in central/eastern Europe and Russia , 2002 .

[29]  E. Vittinghoff,et al.  Amphetamine-group substances and HIV , 2010, The Lancet.

[30]  D. Celentano,et al.  The social epidemiology of human immunodeficiency virus/acquired immunodeficiency syndrome. , 2004, Epidemiologic reviews.

[31]  T. Rhodes,et al.  The social structural production of HIV risk among injecting drug users. , 2005, Social science & medicine.

[32]  C. Beyrer,et al.  Marked ethnic differences in HIV prevalence and risk behaviors among injection drug users in Dushanbe, Tajikistan, 2004. , 2006, Drug and alcohol dependence.

[33]  C. Latkin,et al.  Correlates of Unsafe Equipment Sharing among Injecting Drug Users in St. Petersburg, Russia , 2009, European Addiction Research.

[34]  J. Dunn,et al.  Rethinking social epidemiology : towards a science of change , 2012 .

[35]  R. Heimer,et al.  Comparing sexual risks and patterns of alcohol and drug use between injection drug users (IDUs) and non-IDUs who report sexual partnerships with IDUs in St. Petersburg, Russia , 2010, BMC public health.

[36]  K. Vranizan,et al.  HIV seroconversion in intravenous drug users in San Francisco, 1985–1990 , 1994, AIDS.

[37]  Matthew Hickman,et al.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review , 2008, The Lancet.

[38]  T. Mainland.  UNGASS COUNTRY PROGRESS REPORT , 2008 .

[39]  A. Whiteside,et al.  The Hiv/aids Epidemic in Ukraine: Its Potential Social and Economic Impact Keywords: Hiv/aids Ukraine Socio-economic Impact Transition Potential 4 , 2022 .

[40]  G. Greenwald.  Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies , 2009 .

[41]  T. Rhodes,et al.  Harm reduction among injecting drug users - evidence of effectiveness , 2010 .

[42]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[43]  K. Nelson,et al.  Not All Injection Drug Users Are Created Equal: Heterogeneity of HIV, Hepatitis C Virus, and Hepatitis B Virus Infection in Georgia , 2008, Substance use & misuse.

[44]  R. Heimer,et al.  The Potential for Bridging of HIV Transmission in the Russian Federation: Sex Risk Behaviors and HIV Prevalence among Drug Users (DUs) and their Non-DU Sex Partners , 2009, Journal of Urban Health.

[45]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[46]  L. Cusick.  Widening the harm reduction agenda: From drug use to sex work , 2006 .

[47]  R. Jurgens.  "Nothing about us without us" - greater, meaningful involvement of people who use illegal drugs: a public health, ethical, and human rights imperative. , 2005 .

[48]  K. Blankenship,et al.  Structural Interventions: Concepts, Challenges and Opportunities for Research , 2006, Journal of Urban Health.

[49]  R. Heimer,et al.  High HIV Prevalence, Suboptimal HIV Testing, and Low Knowledge of HIV-Positive Serostatus Among Injection Drug Users in St. Petersburg, Russia , 2010, AIDS and Behavior.

[50]  T. Rhodes.  The ‘risk environment’: a framework for understanding and reducing drug-related harm , 2002 .

[51]  H. Qian,et al.  HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey , 2009, Harm reduction journal.

[52]  N. Krieger,et al.  The impact of a police drug crackdown on drug injectors' ability to practice harm reduction: a qualitative study. , 2005, Social science & medicine.

[53]  C. Vega,et al.  United Nations Office for Drugs and Crime (UNODC) , 2013 .

[54]  T. Rhodes,et al.  Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia , 2009, AIDS care.

[55]  T. Rhodes,et al.  Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. , 2010, Addiction.

[56]  A. Neaigus,et al.  Injecting equipment sharing and perception of HIV and hepatitis risk among injecting drug users in Budapest , 2007, AIDS care.

[57]  J. Lazarus,et al.  HIV/AIDS in the transitional countries of Eastern Europe and Central Asia. , 2005, Clinical medicine.

[58]  A. Verster,et al.  Enabling approaches for HIV/AIDS prevention: can we modify the environment and minimize the risk? , 1995, AIDS.

[59]  B. Kolarić,et al.  Epidemiology of HIV infection and AIDS in Croatia--an overview. , 2006, Collegium antropologicum.

[60]  D. D. Des Jarlais,et al.  Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users , 2006, International journal of STD & AIDS.

[61]  R. Ahas,et al.  Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors , 2010, Sexually Transmitted Infections.

[62]  A. Uusküla,et al.  The HIV prevention needs of injection drug users in Estonia , 2007, International journal of STD & AIDS.

[63]  J. Schmitz,et al.  Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. , 1998, American journal of public health.

[64]  C. Latkin,et al.  The relationship between social network characteristics and exchanging sex for drugs or money among drug users in Baltimore, MD, USA , 2003, International journal of STD & AIDS.

[65]  David A. Leon,et al.  Social transition and substance abuse. , 2005, Addiction.

[66]  P. Griffiths,et al.  Monitoring trends in illicit drug use in Europe: an overview of the work of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) , 2008 .

[67]  James I. Charlton.  Nothing About Us Without Us: Disability Oppression and Empowerment , 1998 .

[68]  T. Rhodes,et al.  Transition and the HIV risk environment , 2005, BMJ : British Medical Journal.

[69]  K. Dolan,et al.  HIV in prison in low-income and middle-income countries. , 2007, The Lancet. Infectious diseases.

[70]  P. Griffiths,et al.  Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe. , 2008, Drug and alcohol review.

[71]  Ferenc Márványkövi,et al.  Sex and Drugs: The Correlations of Injecting Drug Users' Risk Perception and Behavioral Patterns , 2009, Substance use & misuse.

[72]  S. Aral,et al.  Overview: the role of emergent properties of complex systems in the epidemiology and prevention of sexually transmitted infections including HIV infection , 2010, Sexually Transmitted Infections.

[73]  K. Todadze,et al.  Implementation of drug substitution therapy in Georgia. , 2008, Central European journal of public health.

[74]  T. Rhodes,et al.  Harm reduction and the mainstream , 2010 .

[75]  A. Nardone,et al.  Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. , 2009, American Journal of Public Health.

[76]  L. Johnston,et al.  Correlates of HIV Risk Among Injecting Drug Users in Sixteen Ukrainian Cities , 2010, AIDS and Behavior.

[77]  N. Binkin,et al.  Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. , 1994, AIDS care.

[78]  A. Neaigus,et al.  Marginalized and Socially Integrated Groups of IDUs in Hungary: Potential bridges of HIV infection , 2005, Journal of Urban Health.

[79]  Peter Vickerman,et al.  Model Projections on the Required Coverage of Syringe Distribution to Prevent HIV Epidemics Among Injecting Drug Users , 2006, Journal of acquired immune deficiency syndromes.

[80]  R. D’Aquila,et al.  Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. , 1992, AIDS care.

[81]  L. Poretsky,et al.  Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. , 1990, Archives of internal medicine.

[82]  P. Bjerregaard.  Rapid Socio-Cultural Change and Health in the Arctic , 2001, International journal of circumpolar health.

[83]  D. Kissin,et al.  Multicity HIV seroprevalence in street youth, Ukraine , 2010, International journal of STD & AIDS.

[84]  A. Verster,et al.  Interventions to reduce HIV transmission related to injecting drug use in prison. , 2009, The Lancet. Infectious diseases.

[85]  J. Parry,et al.  High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment , 2006, AIDS.

[86]  J. Montaner,et al.  The war on drugs: a devastating public-policy disaster , 2009, The Lancet.

[87]  R. Heimer.  Community coverage and HIV prevention: assessing metrics for estimating HIV incidence through syringe exchange. , 2008, The International journal on drug policy.

[88]  L. Degenhardt,et al.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS , 2006, Sexually Transmitted Infections.

[89]  J. Parry,et al.  Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. , 2006, Addiction.

[90]  T. Rhodes,et al.  Access to syringes in three Russian cities: implications for syringe distribution and coverage. , 2008, The International journal on drug policy.

[91]  T. Hallett,et al.  HIV and risk environment for injecting drug users: the past, present, and future , 2010, The Lancet.

[92]  Matthew Hickman,et al.  HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage , 2010, The Lancet.

[93]  Chris Hall,et al.  Social epidemiology and complex system dynamic modelling as applied to health behaviour and drug use research. , 2009, The International journal on drug policy.

[94]  M. Mckee,et al.  Huge variation in Russian mortality rates 1984–94: artefact, alcohol, or what? , 1997, The Lancet.

[95]  J. Carr,et al.  Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. , 2009, AIDS research and human retroviruses.

[96]  J. Begovac,et al.  Twenty years of human immunodeficiency virus infection in Croatia--an epidemic that is still in an early stage. , 2006, Collegium antropologicum.

[97]  M. Kals,et al.  High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. , 2008, Journal of public health.

[98]  M. Kals,et al.  Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia , 2011, BMC public health.

[99]  R. Heimer,et al.  Stimulant use in Central & Eastern Europe: How Recent Social History Shaped Current Drug Consumption Patterns , 2009 .

[100]  M. Jauffret-Roustide,et al.  The fast and furious : Cocaine, amphetamines and harm reduction , 2010 .

[101]  P. Aggleton,et al.  Structural approaches to HIV prevention , 2008, The Lancet.

[102]  R. Booth,et al.  Predictors of HIV sero-status among drug injectors at three Ukraine sites , 2006, AIDS.

[103]  C. del Rio,et al.  Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. , 2006, Drug and alcohol dependence.

[104]  K. Fischer,et al.  High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia , 2007, International journal of STD & AIDS.

[105]  T. Rhodes,et al.  Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed , 2010, The Lancet.

[106]  J. Dewhurst.  Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence , 2010, AIDS care.

[107]  J. Hass.  Republic of Belarus , 2019, IMF Staff Country Reports.

[108]  D. Hartel,et al.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. , 1998, Public health reports.

[109]  Jie Chen,et al.  Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia , 2000, AIDS.

[110]  J. Parry,et al.  Changes in HIV Prevalence and Risk Among New Injecting Drug Users in a Russian City of High HIV Prevalence , 2008, Journal of acquired immune deficiency syndromes.

[111]  T. Rhodes,et al.  Barriers to accessing drug treatment in Russia: a qualitative study among injecting drug users in two cities. , 2006, Drug and alcohol dependence.

[112]  R. Atun,et al.  Sex, drugs and economic behaviour in Russia: a study of socio-economic characteristics of high risk populations. , 2011, The International journal on drug policy.

[113]  A. Raj,et al.  Correlates of Any Condom Use Among Russian Narcology Patients Reporting Recent Unprotected Sex , 2009, AIDS and Behavior.

[114]  C. Latkin,et al.  Liquid Drugs and High Dead Space Syringes May Keep HIV and HCV Prevalence High – A Comparison of Hungary and Lithuania , 2010, European Addiction Research.

[115]  A. Neaigus,et al.  Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary. , 2009, European journal of public health.

[116]  J. Parry,et al.  Effects of sex work on the prevalence of syphilis among injection drug users in 3 Russian cities. , 2007, American journal of public health.

[117]  T. Rhodes,et al.  Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C risk , 2008 .

[118]  D. Vlahov,et al.  Personal network characteristics as antecedents to needle-sharing and shooting gallery attendance , 1995 .

[119]  L. Palinkas,et al.  Reconciling incongruous qualitative and quantitative findings in mixed methods research: exemplars from research with drug using populations. , 2012, The International journal on drug policy.

[120]  C. Beyrer,et al.  Time to act: a call for comprehensive responses to HIV in people who use drugs , 2010, The Lancet.

[121]  Guidelines for second generation HIV Surveillance , 2000 .

[122]  I. Bozicevic,et al.  Unsafe Injection and Sexual Risk Behavior among Injecting Drug Users in Georgia , 2011, Journal of Urban Health.

[123]  P. Biernacki,et al.  TARGETED SAMPLING: OPTIONS FOR THE STUDY OF HIDDEN POPULATIONS , 1989 .